Interferon-alpha activity may be used routinely in clinical settings as a biomarker for cutaneous lupus erythematosus and ...

Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing ...

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of ...

Research over the past decade has revealed multiple potential mechanisms by which dendritic cells contribute to the immunopathogenesis of systemic lupus erythematosus. Genetic abnormalities in ...

Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.

Future Rheumatol. 2008;3(3):269-279. These phenotypic abnormalities, at least in part, appear to be intrinsic to the mDCs, as the addition of lupus serum to healthy control or lupus mDCs could not ...

Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...

Long-term use of glucocorticoids (GCs) for the treatment of lupus is very common, however, it has also been associated with side effects like high blood pressure, diabetes, infection, and osteoporosis ...

A 23-year-old white woman with systemic lupus erythematosus (SLE ... cAPS was not thought to have a critical role in the pathogenesis of her coma. Medications were not thought to have induced ...

EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...